+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

EditorialOpen Access

Does MIDH Inhibitors is a Promising Therapy?

Nahla A M Hamed*

DOI: 10.26717/BJSTR.2017.01.000197

  • Author Information Open or Close
    • Professor of Hematology, Faculty of Medicine, Alexandria University, Egypt

    Corresponding author: Nahla A M Hamed, Professor of Hematology, Faculty of Medicine, Alexandria University, Egypt

Received: July 11, 2017;   Published: July 18, 2017

To view the Full Article   Peer-reviewed Article PDF


IDH are key metabolic enzymes that play a role in mitochondrial oxidative phosphorylation, glutamine metabolism, lipogenesis, glucose sensing, and regulation of cellular redox status. Mutations in IDH1 and IDH2 proteins catalyze the reduction of α-KG to 2-HG. The abnormal production of the oncometabolite 2-HG promote tumorigenesis. Depending on the associated genomic aberrations and the cellular context, the oncogenic potential of IDH1/2 mutations ranges from an initiating event - promoting transformation - to a secondary oncogenic event conferring selective advantage to cancer cells.

Abbreviation: IDH1 and IDH2: Isocitrate Dehydrogenase 1 and 2; α-KG:-α ketoglutarate; 2-HG: 2-hydroxyglutarate; TET: Ten Eleven Translocation; mIDH: Mutant IDH; HIF: Hypoxia Induced Factor; PARP: Polyadenosine 5ʹ Diphosphate Ribose; HR: Homologous Recombination

Introduction| Future Therapy| Conclusion/a>| References|